Posted by Michael Wonder on 20 Mar 2024
Phanes Therapeutics' PT886 granted fast track designation for the treatment of patients with metastatic claudin 18.2 positive pancreatic adenocarcinoma by the FDA
20 March 2024 - Phanes Therapeutics announced today that the US FDA has granted fast track designation to PT886 for the treatment of patients with metastatic claudin 18.2 positive pancreatic adenocarcinoma.
PT886 was also granted orphan drug designation for the treatment of pancreatic cancer by the FDA in 2022.
